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Abstract 
A hexanucleotide repeat expansion in the gene C9orf72 is the most common genetic 
cause of both amyotrophic lateral sclerosis and frontotemporal dementia. 
Pathogenesis may occur either due to loss of function of the C9orf72 gene, or a toxic 
gain of function, via the production of repetitive sense and antisense RNA and/or 
repetitive dipeptide repeat proteins. Recently, mouse knockouts have suggested that 
a loss of function of C9orf72 alone is insufficient to lead to neurodegeneration, whilst 
overexpression of hexanucleotide DNA is sufficient in a wide range of model 
systems. Additionally, models have now been created to attempt to study the effects 
of repetitive RNA and dipeptide proteins in isolation and thus determine their 
relevance to disease. 
Introduction 
 
A non-coding hexanucleotide repeat expansion in C9orf72 is the most common 
genetic cause of both frontotemporal dementia (FTD) and amyotrophic lateral 
sclerosis (ALS)[1,2]. The mutation is a (GGGGCC)n expansion with unaffected 
individuals typically carrying fewer than 30 repeats, while patients harbour several 
hundreds to thousands[1–4]. Affected individuals present clinically with either ALS, 
FTD, or both [1,2,5] and display TDP-43 pathology[1,6]. 
 
Three mechanisms have been proposed to explain how C9orf72 hexanucleotide 
expansions lead to ALS/FTD (C9ALS/FTD), either by loss-of-function or by two 
different gain-of-function mechanisms (Figure 1A-C): 
(1) The expansion leads to reduced transcription of C9orf72, leading to 
haploinsufficiency (Figure 1A).  
(2) Repeat-containing sense and antisense RNA transcripts accumulate and 
sequester RNA binding proteins (Figure 1B).  
(3) Sense and antisense RNA are translated by repeat-associated, non-ATG 
initiated (RAN) translation into five, potentially toxic, repetitive dipeptide 
proteins (DPRs) (Figure 1C). 
We will critically review newly developed cellular and animal C9FTD/ALS models and 
discuss the insight they provide into the role of each proposed mechanism in disease 
pathogenesis.  
 
Loss of function 
 
C9orf72 has three splice variants that either harbour the expansion in the first intron 
of the gene (variants 1 and 3) or the promoter (variant 2)[1]. Variant 1 comprises 
exons 1-5 and encodes a short protein isoform (222 amino acids: C9ORF72-S) while 
variants 2 and 3 encode the long isoform (481 amino acids: C9ORF72-L)[1,7]. 
Analysis of post mortem C9ALS/FTD brains showed reduced C9orf72 transcript [1,8–
13] and reduced protein[7,11,14]. This may be a consequence of epigenetic 
silencing[8,10,15,16] or abortive transcription[17]. Reduced C9orf72 levels in patients 
led to the suggestion that loss of normal C9orf72 function leads to pathogenesis. 
However, only a single sporadic ALS patient has ever been found to carry a mutation 
potentially capable of causing a heterozygous loss of function, and it is unclear if this 
mutation is causative of the disease state[18,19]. Additionally, a patient homozygous 
for the repeat expansion had a similar clinical phenotype to heterozygote patients, 
rather than a much more severe phenotype typical of homozygous loss of function 
mutations[12]. Therefore the genetic evidence currently supports a gain of function 
rather than a loss of function mechanism as the primary cause of disease [20]. 
However, loss of function models are providing evidence in favour of an important 
role for C9orf72 in cellular functions relevant to neuronal function, which suggests 
loss of function could contribute to the disease process. 
 
 C9orf72 is homologous to members of the DENN (differentially expressed in normal 
and neoplastic cells) domain containing protein family, and is predicted to be 
involved in membrane trafficking as a Rab guanine exchange factor[21]. C9ORF72-L 
forms a complex with SMCR8 and WDR41[22–27] and is involved in the induction of 
autophagy[22,23,25,28,29], whilst C9ORF72-S is localised at the nuclear membrane 
in patient brain and has been suggested to be involved  in nucleocytoplasmic 
transport[7]. Work in cell lines or primary rodent neuronal cultures has demonstrated 
that knockdown of C9orf72 is sufficient to induce P62-positive puncta[23,28], 
consistent with autophagic dysfunction, and one study has observed the 
mislocalisation of phosphorylated TDP-43 after C9orf72 knockdown[23]. 
 
Several animal models have been produced in which the expression of genes 
orthologous to C9orf72 are reduced (Table 1, Figure 1D). Knockout of the C. elegans 
ortholog of C9orf72 (ALFA-1) led to progressive age-related paralysis[30]. Injection of 
antisense morpholino oligonucleotides during zebrafish development led to altered 
axonal branching in larval motor neurons and an associated motor phenotype[9]. 
Consistent with this finding, it was recently shown that C9orf72 regulates actin 
dynamics and axon growth in cultured motor neurons[14].  
 
Several groups have tested the effect of reduced expression of the mouse ortholog 
of C9orf72 (3110043O21Rik), either in a tissue-specific or ubiquitous manner (Table 
1). The results of these studies are strikingly concordant; no overt neurodegeneration 
occurs in response to partial or complete loss of C9orf72 function. Furthermore, no 
mislocalisation of TDP-43 is observed[31–33]. These findings clearly suggest that 
loss of C9orf72 function is not sufficient to cause disease. Interestingly, however, 
whilst neuron-specific knockdown or knockout had no pathogenic effects[31,34], 
whole-genome knockout resulted in immune system phenotypes, including 
splenomegaly (enlarged spleen) and lymphandenomegaly (enlarged lymph nodes) 
[25,33,35–37]. These findings are particularly interesting given the increasing 
evidence supporting a role for the immune system in a wide range of 
neurodegenerative diseases[38]. 
  
 
Gain of RNA and Protein Function 	
Gain of Function Pathologies 
A typical feature of many repeat expansion diseases is the formation of RNA foci: 
aggregates of RNA which are capable of sequestering RNA-binding proteins [39]. In 
C9ALS/FTD, repeat-expanded RNA is transcribed in both sense and antisense 
directions and forms both nuclear, and rarer, cytoplasmic sense and antisense RNA 
foci across multiple patient brain regions, and in patient derived cell lines (Figure 1B) 
[1,34,40–48]. Several studies have identified RNA-binding proteins (RBPs) 
sequestered by sense and antisense transcripts. Therefore reduced availability of 
these RBPs may play a role in the disease state (reviewed in [49]). 
In addition to the formation of RNA foci, sense and antisense expansion-containing 
RNA is also RAN translated in all three reading frames, producing five, potentially 
toxic dipeptide-repeat proteins (DPRs)[43,50,51] (Figure 1C). DPRs form p62-
positive, TDP43-negative inclusions, abundant in the neocortex, hippocampus and 
cerebellum[50–52]. Typically, poly-GA inclusions are the most abundant, followed by 
poly-GP and poly-GR, whilst poly-AP and poly-PR inclusions are rare [47,53,54]. 
Pathological studies have examined DPR inclusions in C9FTD, C9ALS or 
C9FTD/ALS patients, and have not found consistent correlations between RAN 
protein pathology and clinical phenotype, TDP-43 pathology or neurodegeneration 
[52,53,55]. However, a recent study found that levels of soluble poly-GP in the 
cerebellum correlate positively with cognitive impairment [56]. 
 
Pure GGGGCC repeat models 
In order to determine whether a gain of function is sufficient to induce a disease 
phenotype, several groups have overexpressed GGGGCC repeats and 
demonstrated deleterious phenotypes in cell culture [45,57–59], C.elegans [60] , 
Zebrafish[45], and Drosophila[58,61–63] models, providing evidence that C9orf72 
mutation associated toxic gain of function is sufficient to cause disease (Figure 1E).  
 
Recently, several mouse models of C9orf72 expansions have been produced, either 
using overexpression of hexanucleotide repeats [64], or integration of human 
bacterial artificial chromosomes (BACs) containing expanded hexanucleotide 
DNA[35,37,66,67] (Table 2). Whilst all studies demonstrated that expression of 
repeat-expanded RNA led to foci formation, and resulted in at least some DPR 
species, the resultant phenotypes of the various mouse models were markedly 
different.  
 
Overexpression of 66 GGGGCC repeats using adeno-associated viruses (AAVs) led 
to accumulation of RNA foci, DPR and TDP-43 pathology as well as neuronal loss 
with cognitive and motor dysfunction[64]. Generation of BAC mice led variously to: 
no cognitive or motor abnormalities[65,66], hippocampus-related cognitive 
dysfunction[37] or either acute or progressive phenotypes marked by behavioural 
and motor abnormalities and reduced survival[67]. The discrepancies between these 
outcomes seem unlikely to be due to differences in the amount of 5’ or 3’ C9orf72 
flanking sequence present in each BAC, as the BACs from phenotypic and non-
phenotypic mice overlapped (Table 2). It is notable that the different models were 
produced in different genetic backgrounds (Table 2), which can strongly influence 
neurodegenerative phenotypes in mice [68]. Additionally, toxicity may be dependent 
on level of expression. For example, Chew et al. (2015) [64] and Liu et al. (2016) [67] 
found that strong overexpression of relatively short repeat lengths to be toxic, whilst 
Jiang et al. (2016) [37] found that foci formation and DPR accumulation were 
positively correlated with repeat-expansion-containing RNA expression levels. It is 
thus possible that the required level of putatively toxic RNA or DPR species was not 
met in non-phenotypic mice.  
 
Despite these differences, the fact that expression of hexanucleotide RNA can lead 
to behavioural and motor abnormalities underpinned by neurodegeneration, 
especially in a BAC context where expression is driven by the endogenous C9orf72 
promoter, strongly suggests that a gain of function alone is sufficient to drive 
pathogenesis. It is notable that phenotypic mice either displayed TDP-43 
inclusions[64,67] or increased TDP-43 phosphorylation[37], providing further 
evidence that neurodegeneration is driven primarily through a toxic gain of function 
leading to TDP-43 pathology. 
 
 
  
RNA or Protein? 
 
Whilst pure GGGGCC repeat expression models provide evidence of a toxic gain of 
function, they cannot distinguish whether toxicity is primarily mediated by RNA or 
DPRs, which has led to considerable debate in the field.   
 
RNA-only models  	
In order to study the potential role of RNA toxicity in isolation, it is necessary to 
design models where GGGGCC repeat containing RNA is expressed whilst RAN 
translation is suppressed. GGGGCC repeat RNA (36 and 103 repeats) is toxic to 
Drosophila neurons when overexpressed. Conversely, when the repeats are 
interrupted by regularly interspersed stop codons in every reading frame RAN 
translation and toxic phenotypes are completely prevented, even when up to ~288 
interrupted repeats are expressed[61,69]. This suggests that DPRs are the major 
contributor to toxicity in Drosophila models of C9orf72. In concordance with this 
conclusion, overexpression of sense hexanucleotide RNA from the intron of a 
transgene in Drosophila is sufficient for the formation of numerous RNA foci but does 
not cause toxicity, because efficient splicing of intronic repeat RNA prevents its 
nuclear export and RAN translation[70] (Figure 1F).   
 
Interestingly, in a BAC mouse model, the presence of multiple copies of short repeat 
lengths (29-36 repeats) produced only DPRs and not nuclear RNA foci, but TDP-43 
pathology and neurodegenerative phenotypes were still observed[67](Table 2). 
Together these results suggest that RNA foci are dispensable for the induction of 
disease pathogenesis in Drosophila and mice. However, it is difficult to rule out a 
possible toxic effect of RNA that does not form foci, or cytoplasmic RNA, a prospect 
that has recently been raised in iPSC-derived neurons[63].   
 
On the other hand, a different Drosophila model carrying an inducible construct 
capable of expression of 30 hexanucleotide repeats interrupted by a 6-base pair 
restriction endonuclease cut site[58] does not produce detectable DPRs when 
expressed in photoreceptor neurons or pan-neuronally despite showing degenerative 
phenotypes, suggesting that toxicity in this model is primarily driven by RNA[71]. It 
should be noted however, that poly-GR becomes detectable upon strong 
overexpression in these flies, suggesting that there may be poly-GR present at 
undetectable levels, which may contribute to the observed phenotypes in lower 
expressing flies. Additionally, it has been shown that expression of 42 GGGGCC 
repeats from the intron of a transgene is toxic to mouse primary cortical and motor 
neurons, with the development of abundant RNA foci but no detectable DPR 
accumulation[59].  
 
These results suggest that the potential toxicity of expanded RNA may depend on 
subcellular localisation and the model system employed. Additionally, no study has 
attempted to assess the effect of overexpression of antisense RNA in isolation. Thus, 
further characterisation of existing models as well as development of antisense 
models will be required to fully assess the contribution of RNA toxicity in 
C9ALS/FTD.  
 
Protein-only models  
 
Protein-only models include exogenous application of recombinant DPR peptides 
and the use of codon degeneracy (individual amino acids can be encoded by more 
than one triplet codon) to generate transgenic models that overexpress individual 
DPRs in an ATG-driven manner, allowing comparison of their relative effects (Figure 
1G, Table 3). Although DPRs may be present at higher levels than those typically 
observed in patient tissue, there is a broad consensus across multiple model 
systems that arginine-rich DPRs (poly-GR and Poly-PR) are highly toxic (Table 3), 
with other dipeptide proteins, most notably poly-GA, being identified as toxic in some 
model systems [61,72–75].   
 
In order to determine mechanisms of DPR toxicity, several groups have attempted to 
identify arginine-DPR interacting proteins using immunoprecipitation of DPRs from 
cell lines with subsequent mass-spectrometric identification of interacting 
proteins[76–80]. Recently, two studies have demonstrated that arginine-rich DPR 
interactors are enriched in low complexity regions (LCRs), typically found in protein 
constituents of membrane-less organelles such as stress granules, nuclear speckles 
and nucleoli[79,80]. The exact mechanism(s) by which the arginine-rich DPRs are 
toxic to neurons are still not fully resolved, however translational repression[77,80], 
mitochondrial dysfunction[78], nucleolar dysfunction[76,81],  and disruption of 
nucleocytoplasmic transport have all been implicated[62,71,82,83]. 
 
It should be noted that although poly-GA is seemingly less toxic than the arginine rich 
DPRs, it has been shown to exert mild toxicity when expressed in Drosophila 
neurons[61] and in cell culture, including primary rodent neurons[72–75]. Recently it 
was demonstrated that AAV-mediated overexpression of poly-GA dipeptides in mice 
led to neurodegeneration and, cognitive and motor dysfunction[74]. However, only 
rare TDP-43 inclusions were observed, indicating that accumulation of poly-GA 
protein alone may be insufficient to lead to the full disease state[74]. Future studies 
will be required to determine whether arginine-rich DPR overexpression is sufficient 
to induce ALS/FTD associated phenotypes in mice.  
 
Synergistic Mechanisms 
 
Although researchers have aimed to isolate different possible mechanisms of toxicity 
in order to elucidate their potential role in disease, it is possible that individual 
mechanisms act synergistically to induce the disease state.  
 
Whilst loss of function of C9orf72 alone is unlikely to be sufficient to induce disease, 
cell culture studies suggest that reduced expression of C9orf72 leads to disruption of 
autophagy[22,23,28,29] and autophagic dysfunction has been strongly linked to 
neurodegenerative disease [84]. Therefore the potential role of C9orf72 loss of 
function as a disease modifier should be thoroughly explored. Recently it was 
demonstrated that overexpression of C9orf72 reduces the aggregation of TDP-43 in 
cell culture and a small decrease in C9orf72 expression exacerbated expanded 
ataxin-2 pathology in mouse neurons and zebrafish larvae[23]. The genetic models 
described above, such as knockout mice and mice transgenic for hexanucleotide 
expansions can now be combined to ascertain the degree to which C9orf72 loss of 
function may affect disease phenotypes.  
 
Arginine-rich DPRs are toxic in multiple systems whilst poly-GA has also been shown 
to be toxic to mouse neurons. Interestingly, poly-GA has been demonstrated to 
recruit poly-GR into inclusions when co-expressed in human cells [85] and in 
Drosophila, resulting in a lessening of poly-GR toxicity [86]. Whether interaction 
between the individual DPRs acts to enhance or suppress their toxicity is thus a point 
of interest. Additionally, frameshifting during the translation of repetitive proteins has 
been described in other repeat expansion disorders[87]. Whether this occurs in 
C9orf72 mutation carriers is currently unknown, but could potentially lead to the 
production of peptides imbued with the qualities of more than one DPR species.  
 
Conclusions 
 
Recent studies of the mechanism(s) of pathogenesis in C9ALS/FTD have focused on 
attempting to separate potential pathologies in model systems to study them further. 
Although the C9ORF72-L protein has been implicated in the induction of autophagy, 
a number of mouse loss of function models have failed to develop ALS/FTD 
associated phenotypes (Table 1). Expression of expanded GGGGCC repeat DNA is 
extremely toxic in a number of model systems. Recent advances include the 
expression of GGGGCC repeat DNA in mice, which under some circumstances 
display motor dysfunction and behavioural abnormalities with TDP-43 pathology 
(Table 2). Despite the potential shortcomings of the model systems in question, for 
example the incomplete homology of disrupted orthologous genes (see Table 1), or 
the strong overexpression of relatively short repeat lengths employed in many 
models, in combination these results strongly indicate that expression of expanded 
GGGGCC repeats alone are sufficient to cause C9ALS/FTD. 
 
Although it seems likely that the C9orf72 repeat expansions cause toxicity through a 
gain of function it is not clear whether this is primarily mediated by expanded RNA or 
DPR proteins. Several groups have attempted to separate RNA expression from 
DPR production, with clear evidence, albeit in Drosophila models, indicating that 
repeat RNA without the expression of dipeptide proteins may not be toxic. Others 
have studied the relative toxicity of different DPR species by overexpressing 
recodonised protein constructs (Table 3) and overexpressed arginine-containing 
DPRs have been repeatedly independently identified as being toxic. However, 
overexpression of poly-GA is sufficient to induce neurodegeneration in mice, leaving 
the relative contribution of different dipeptides to the toxicity demonstrated in mouse 
models currently unresolved. It will be important to develop models with physiological 
expression levels of the DPRs in order to accurately tease out the contribution of 
each DPR to neuronal dysfunction. It is also likely that the different potential 
mechanisms of toxicity interact in bringing about the disease state. Thus, although 
individual DPRs and hexanucleotide containing RNA have the potential to be toxic, 
the combination of individual, physiological genetic models will be crucial in 
understanding how these pathologies interact and ultimately lead to the full disease 
state.  
  
Figure 1: Potential mechanisms of C9orf72 hexanucleotide expansion toxicity and commonly 
employed genetic models. Three potential mechanisms by which the C9orf72 associated 
hexanucleotide expansioncauses toxicity. A) Epigenetic silencing associated with the repeat 
expansion leads to reduced C9orf72 expression and thus happloinsufficiency. B) The 
hexanucleotide expanded DNA is transcribed in both sense and antisense directions. These 
expanded RNAs form typically, intranuclear aggregates known as RNA foci, which have been 
proposed to sequester RNA binding proteins leading to toxicity. C) Repeat expanded RNAs can 
undergo repeat-associated-non-ATG-initiated (RAN) translation producing repetitive peptides from 
all reading frames without the requirement of an ATG start codon[57]. RAN translation of both sense 
and antisense RNA has been demonstrated to occur in C9ALS/FTD patients, leading to the 
production of five potentially toxic dipeptide repeat proteins (DPRs), these are: poly-glycine-alanine 
(poly-GA), poly-glycine-proline (poly-GP), poly-glycine-arginine (poly-GR), poly-alanine-proline (poly-
AP), and poly-proline-arginine (poly-PR). D) Loss of function of C9orf72 or its orthologous genes in 
other species can be used to study whether a complete or partial loss of C9orf72 in isolation is 
sufficient to induce a disease phenotype (see Table 1) E) Transgenic overexpression of GGGGCC 
repeats, either on their own or as part of a patient derived bacterial artificial chromosome (BAC), 
model both RNA and DPR toxicity, an approach that has recently been applied to generate mouse 
models of the disease (Table 2). F) Two approaches have been used to suppress RAN translation 
and study the effect of hexanucleotide repeat expression in isolation, either expression of relatively 
short stretches of GGGGCC repeats from within a strongly constitutively spliced intronic 
region[59,70] or by regularly interrupting the repeat sequence with stop codons[61]. G) Codon 
degeneracy allows for the engineering of “recodonised” constructs that allow ATG-initiated 
expression of individual dipeptide repeat proteins without an underlying GGGGCC repeat sequence 
(Table 3).  
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Table 1: Comparison of loss of animal studies examining phenotypic effects of loss of function 
of C9orf72 orthologs.  
 
 	
Model Organism Orthologue (%protein identity) Intervention Phenotype Study(s)
C.elegans ALFA-1 (23.6%) Knockout/RNAi silencing Enhanced age-related paralysis phenotype. GABAergic neuronal dysfunction Therrien et al. (2013) [30]
D.rario zC9orf72 (76.1%) Antisense morpholino injection into fertilized eggs
Shortened motor neuron axons, deficits in 
evoked and spontaneous swimming in 
larvae
Ciura et al. (2013) [9]
M.musculus 3110043O21Rik (98.1%) Intraventricular injection of antisense oligonucleotides against C9orf72
No behavioural or motor differences. No 
evidence of TDP-43 pathology. Lagier-tourenne et al. (2013) [34]
Cre-lox mediated brain specific excision of 
exons 4-5
In both heteroyzgous and homozygous 
animals: No alteration in lifespan or grip 
strength. No evidence of TDP-43 pathology 
or neurodegeneration.
Koppers et al. (2015) [31]
Transgenic mice with replacement of 
exons 2-11 with LacZ construct
Reduced motor function in homozygous 
knockouts. Evidence of immune 
dysregulation. No overt neurodegeneration. 
Atanasio et al. (2016) [37]
Transgenic mice with replacement of 
exons 2-6 with LacZ construct
Reduced lifespan in both heterozygote and 
homozygote knockouts. Evidence of 
immune dysregulation. No evidence of 
neurodegeneration. 
Suzuki et al. (2013) [87]; 
Burberry et al. (2016) [35]
CRISPR-cas9 targeted disruption of exon 
4
Reduced survival in mosaic heterozygous 
and compound heterozygous mutants. 
Evidence of immune dysfunction.
Burberry et al. (2016) [35]
Transgenic mice with replacement of 
exons 2-6 with LacZ construct
Reduced lifespan in homozygous 
knockouts. Some mild beahvioural and 
motor dysfunction. Evidence of immune 
dysregulation. No overt neurodegeneration. 
Jiang et al. (2016) [36]
Transgenic mice with replacement of 
exons 2-6 with LacZ construct O'Rourke et al. (2016) [33]
Zinc finger nuclease mediated removal of 
exon 2 start codon O'Rourke et al. (2016) [33]
Cre-lox mediated whole-genome specific 
excision of exons 4-5
Homozygous knockouts display reduced 
survival.  No evidence of motor 
dysfunction. No evidence of TDP-43 
pathology or neurodegeneration. Evidence 
of immune deregulation.
Koppers et al. (2015) [31]; Sudria 
Lopez et al. (2016) [32]
CRISPR-cas9 mediated frameshift 
mutation in exon 2 causing premature 
stop codon affecting variants 1 and 3. 
Evidence of immune dysregulation Sullivan et al. (2016) [25]
No behavioral or motor differences. 
Evidence of immune dysfunction. No 
evidence of TDP-43 pathology or 
neurodegeneration.
			
Table 2: Comparison of mouse models of C9orf72 repeat expansion. 
P=Detected, X=Not detected, ?=Not examined 
XwIncreased	phospho-TDP43	observed	by	immunoblot	vs	non-transgenic,	but	no	mislocalisation	observed.	
Type of 
Transgenic Transgene Information Repeat Length
Genetic 
Background Phenotype Sense Antisense GP GA GR PA PR
TDP-43 
Inclusions Neurodegeneration Study
2 repeats ✖ ? ✖ ✖ ✖ ? ? ✖ None
66 repeats ✔ ? ✔ ✔ ✔ ? ? ✔ Severe
Unknown copy number; ~100-600 repeats 
(F112) ✔ ✔ ✔ ? ? ? ? ✖ None
Unknown copy number; ~100-1000 
repeats (F113) ✔ ✔ ✔ ? ? ? ? ✖ ?
Unknown copy number; 15 repeats ✖ ✖ ✖ ? ? ? ? ✖ ?
Human 
C9orf72 BAC
BAC containing 140.5kb 
upstream and exons 1-5 of 
the C9orf72 gene
2 copies; 300 repeats/500 repeats SJL/B6
Male mice examined. No 
behavioural or motor 
abnormalities. No evidence of 
neuronal dysfunction.
✔ ✔ ✔ ? ? ? ? ✖ None Peters et al. (2015) [66]
1 copy; 450 repeats (high expression) ✔ ✔ ✔ ✔ ✔ ✖ ✖ ✖w Mild
1 copy; 450 repeats (medium expression) ✔ ✔ ✔ ? ? ✖ ✖ ? Mild
1 copy; 450 repeats (low expression) ✔ ✔ ✔ ? ? ✖ ✖ ? ?
1 copy; 110 repeats (medium expression) ✖ ✖ ✖ ? ? ✖ ✖ ? None
1 copy: 500 repeats ✔ ✔ ✔ ✔ ? ? ? ✔
2 copies: 500 repeats/32 repeats ✔ ✔ ✔ ✔ ? ? ? ✔
4 copies: 36/29 repeats ✖ ✖ ✔ ✔ ? ? ? ✔
1 copy: 37 repeats Male and female mice examined, no phenotypes observed ✖ ✖ ✖ ✖ ? ? ? ✖ None
Severe in acute 
end stage animals. 
Moderate in slow 
progressive 
animals. None in 
asymtomatic 
animals.   
Human 
C9orf72 BAC
Human 
C9orf72 BAC
Human 
C9orf72 BAC 
Chew et al. (2015) 
[64]
O'Rourke et al. 
(2015) [65]
Jiang et al. (2016) 
[36]
Liu et al. (2016) 
[67]
AAV based 
overexpression 
with CMV 
promoter. 
CMV promoter. 
Intracerebroventricular 
injection at P0. Repeats 
cloned with 119bp 5' 
flanking region and 100bp 
3' flanking region of the 
C9orf72 gene
BAC containing full 29.6kb 
C9orf72 gene with ~52kb 
upsteam and ~19.4kb 
downstream sequence 
(~98kb total) 
Male mice examined. 66 repeat 
expressing mice demonstrate 
behavioural and motor 
abnormalities.
BAC containing full 
C9orf72 gene region 
(~36kb) with ~110kb 
upstream and ~20kb 
downstream
C57BL/6J
Male mice examined. No 
behavioural or motor 
abnormalities.
BAC containing 140kb 
upstream and exons 1-5 of 
the C9orf72 gene 
C57BL6/CH3 
injected, 
backcrossed 
into C57BL/6
No motor abnormalities in any 
tested line. Male but not female 
medium and high 450 repeat 
expressors display cognitive and 
behavioural dysfunction. 
Foci Pathology Dipeptide Pathology
Male and female mice examined. 
Either acute phenotype, slower 
progressive phenotype 
(symptomatic mice), or 
asymptomatic. Acute phenotype 
characterised by reduced 
survival. Symptomatic mice 
display behavioural and motor 
abnormalities.
FVB/NJ
C57BL/6J
		 	
Table 3: Comparison of studies that compare the toxicity of individual DPRs in different model 
systems. 
Numbers indicate the repeat length(s) tested in the study, note: in some studies the dipeptide proteins are 
epitope tagged.  
*Peptides were exogenously applied to cells rather than overexpressed. Note poly-GA was found to be toxic 
in primary neurons [72–75] but these studies were excluded from the table as they do not compare to other 
DPRs. 
 
 
Study Model system GR PR GA AP GP
Kwon et al. (2014) [80] U2OS cells / human astrocytes 20* 20* Toxic
May	et	al.	(2014)	[72] HEK293	cells 149 175 175 175 80 Mild	or	length	dependent	toxicity
Mizielinska et al. (2014) [61] Drosophila 36; 100 36; 100 36; 100 36; 100 Not	toxic
Wen et al. (2014) [59] Drosophila 50 50 50 Not	tested
Wen et al. (2014) [59] Mouse primary neurons 25-400 25-200 25-400 25-200 25; 50
Wen et al. (2014) [59] Human iPSC derived neurons 50 50
Freibaum et al. (2015) [62] Drosophila 50 50 47
Jovičić et al. (2015) [81] Saccharomyces cerevisiae 50;100 50 50 50
Tao et al. (2015) [75] HEK293 / NSC34 cells 30 30 30 30 30
Yamakawa et al. (2015) [84] Neuro-2a cells 100 100 100 100 100
Yang et al. (2015) [85] Drosophila 80 80 80
Boeynaems et al. (2016) [82] Drosophila 50 25; 50 50 50
Kanekura et al. (2016) [76] NSC34 cells 20* 20* 20*
Lopez-Gonzalez et al. (2016) [77] Human iPSC derived motor neurons 80 80
Lee	et	al.	(2016)	[79] Neuro-2a	cells 50 50 50 50 47
Lee	et	al.	(2016)	[79]	 Drosophila 50 50 50 50 47
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